Headlines about Oncomed Pharmaceuticals (NASDAQ:OMED) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Oncomed Pharmaceuticals earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.5845872938565 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news stories that may have effected Accern’s analysis:

OMED has been the subject of a number of research analyst reports. Jefferies Group set a $5.00 target price on Oncomed Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 25th. Cantor Fitzgerald restated a “hold” rating and set a $6.00 target price on shares of Oncomed Pharmaceuticals in a report on Tuesday, September 19th. Zacks Investment Research upgraded Oncomed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a report on Wednesday, October 4th. Finally, SunTrust Banks restated a “hold” rating and set a $4.00 target price on shares of Oncomed Pharmaceuticals in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $5.94.

Oncomed Pharmaceuticals (NASDAQ OMED) traded down $0.02 during mid-day trading on Tuesday, reaching $3.95. The company’s stock had a trading volume of 218,200 shares, compared to its average volume of 282,089. Oncomed Pharmaceuticals has a 52 week low of $2.91 and a 52 week high of $10.89.

Oncomed Pharmaceuticals (NASDAQ:OMED) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.13. The company had revenue of $5.11 million during the quarter, compared to analyst estimates of $6.25 million. Oncomed Pharmaceuticals’s revenue for the quarter was down 13.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.77) EPS. equities research analysts expect that Oncomed Pharmaceuticals will post -1.62 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Oncomed Pharmaceuticals (OMED) Receives Daily Media Sentiment Rating of 0.19” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.watchlistnews.com/oncomed-pharmaceuticals-omed-receives-daily-media-sentiment-rating-of-0-19/1773219.html.

Oncomed Pharmaceuticals Company Profile

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).

Insider Buying and Selling by Quarter for Oncomed Pharmaceuticals (NASDAQ:OMED)

Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.